Literature DB >> 10486318

Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors.

J M Varley1, G McGown, M Thorncroft, L A James, G P Margison, G Forster, D G Evans, M Harris, A M Kelsey, J M Birch.   

Abstract

We have analyzed a panel of 14 cases of childhood adrenocortical tumors unselected for family history and have identified germline TP53 mutations in >80%, making this the highest known incidence of a germline mutation in a tumor-suppressor gene in any cancer. The spectrum of germline TP53 mutations detected is remarkably limited. Analysis of tumor tissue for loss of constitutional heterozygosity, with respect to the germline mutant allele and the occurrence of other somatic TP53 mutations, indicates complex sequences of genetic events in a number of tumors. None of the families had cancer histories that conformed to the criteria for Li-Fraumeni syndrome, but, in some families, we were able to demonstrate that the mutation had been inherited. In these families there were gene carriers unaffected in their 40s and 50s, and there were others with relatively late-onset cancers. These data provide evidence that certain TP53 alleles confer relatively low penetrance for predisposition to the development of cancer, and they imply that deleterious TP53 mutations may be more frequent in the population than has been estimated previously. Our findings have considerable implications for the clinical management of children with andrenocortical tumors and their parents, in terms of both genetic testing and the early detection and treatment of tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10486318      PMCID: PMC1288270          DOI: 10.1086/302575

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  51 in total

1.  Simultaneous adrenocortical carcinoma and ganglioneuroblastoma in a child with Turner syndrome and germline p53 mutation.

Authors:  E K Pivnick; W L Furman; G V Velagaleti; J J Jenkins; N A Chase; R C Ribeiro
Journal:  J Med Genet       Date:  1998-04       Impact factor: 6.318

2.  Astrocytomas and choroid plexus tumors in two families with identical p53 germline mutations.

Authors:  A Vital; P P Bringuier; H Huang; F San Galli; J Rivel; S Ansoborlo; J M Cazauran; L Taillandier; P Kleihues; H Ohgaki
Journal:  J Neuropathol Exp Neurol       Date:  1998-11       Impact factor: 3.685

3.  Overview of RB gene mutations in patients with retinoblastoma. Implications for clinical genetic screening.

Authors:  J W Harbour
Journal:  Ophthalmology       Date:  1998-08       Impact factor: 12.079

4.  Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family.

Authors:  J M Varley; P Chapman; G McGown; M Thorncroft; G R White; M J Greaves; D Scott; A Spreadborough; K J Tricker; J M Birch; D G Evans; R Reddel; R S Camplejohn; J Burn; J M Boyle
Journal:  Oncogene       Date:  1998-06-25       Impact factor: 9.867

5.  Association of germline p53 mutation with MLL segmental jumping translocation in treatment-related leukemia.

Authors:  C A Felix; M D Megonigal; D S Chervinsky; D G Leonard; N Tsuchida; S Kakati; A M Block; J Fisher; M Grossi; K I Salhany; S N Jani-Sait; P D Aplan
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

6.  Distinct RB1 gene mutations with low penetrance in hereditary retinoblastoma.

Authors:  D R Lohmann; B Brandt; W Höpping; E Passarge; B Horsthemke
Journal:  Hum Genet       Date:  1994-10       Impact factor: 4.132

7.  Familial brain tumour syndrome associated with a p53 germline deletion of codon 236.

Authors:  J Lübbe; K von Ammon; K Watanabe; M E Hegi; P Kleihues
Journal:  Brain Pathol       Date:  1995-01       Impact factor: 6.508

8.  Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.

Authors:  J M Birch; V Blair; A M Kelsey; D G Evans; M Harris; K J Tricker; J M Varley
Journal:  Oncogene       Date:  1998-09-03       Impact factor: 9.867

9.  A novel missense mutation in patients from a retinoblastoma pedigree showing only mild expression of the tumor phenotype.

Authors:  J K Cowell; B Bia
Journal:  Oncogene       Date:  1998-06-18       Impact factor: 9.867

10.  Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours.

Authors:  Z Sedlacek; R Kodet; V Kriz; E Seemanova; P Vodvarka; P Wilgenbus; J Mares; A Poustka; P Goetz
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

View more
  64 in total

1.  Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation.

Authors:  Lindsay B Robertson; Georgina N Armstrong; Bianca D Olver; Amy L Lloyd; Sanjay Shete; Ching Lau; Elizabeth B Claus; Jill Barnholtz-Sloan; Rose Lai; Dora Il'yasova; Joellen Schildkraut; Jonine L Bernstein; Sara H Olson; Robert B Jenkins; Ping Yang; Amanda Lynn Rynearson; Amanda L Rynerason; Margaret Wrensch; Lucie McCoy; John K Wienkce; Bridget McCarthy; Faith Davis; Nicholas A Vick; Christoffer Johansen; Hanne Bødtcher; Siegal Sadetzki; Revital Bar-Sade Bruchim; Galit Hirsh Yechezkel; Ulrika Andersson; Beatrice S Melin; Melissa L Bondy; Richard S Houlston
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

Review 2.  Adrenocortical stem and progenitor cells: implications for adrenocortical carcinoma.

Authors:  Derek P Simon; Gary D Hammer
Journal:  Mol Cell Endocrinol       Date:  2012-01-13       Impact factor: 4.102

Review 3.  Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes.

Authors:  D G R Evans; J M Birch; R T Ramsden; S Sharif; M E Baser
Journal:  J Med Genet       Date:  2005-09-09       Impact factor: 6.318

Review 4.  Towards an understanding of the role of p53 in adrenocortical carcinogenesis.

Authors:  Jonathan D Wasserman; Gerard P Zambetti; David Malkin
Journal:  Mol Cell Endocrinol       Date:  2011-09-10       Impact factor: 4.102

Review 5.  Two hits revisited again.

Authors:  I P Tomlinson; R Roylance; R S Houlston
Journal:  J Med Genet       Date:  2001-02       Impact factor: 6.318

Review 6.  Development of adrenal cortex zonation.

Authors:  Yewei Xing; Antonio M Lerario; William Rainey; Gary D Hammer
Journal:  Endocrinol Metab Clin North Am       Date:  2015-06       Impact factor: 4.741

7.  Late-onset common cancers in a kindred with an Arg213Gln TP53 germline mutation.

Authors:  Mariëlle W G Ruijs; Senno Verhoef; Gea Wigbout; Roelof Pruntel; Arno N Floore; Daphne de Jong; Laura J van T Veer; Fred H Menko
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

8.  Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population.

Authors:  S Mitra; S Banerjee; C Misra; R K Singh; A Roy; A Sengupta; C K Panda; S Roychoudhury
Journal:  J Clin Pathol       Date:  2006-11-01       Impact factor: 3.411

9.  p53: a molecular marker for the detection of cancer.

Authors:  Mark T Boyd; Nikolina Vlatkovic
Journal:  Expert Opin Med Diagn       Date:  2008-09

10.  High frequency of loss of heterozygosity at 11p15 and IGF2 overexpression are not related to clinical outcome in childhood adrenocortical tumors positive for the R337H TP53 mutation.

Authors:  Roberto Rosati; Flavia Cerrato; Mabrouka Doghman; Mara A D Pianovski; Guilherme A Parise; Gislaine Custódio; Gerard P Zambetti; Raul C Ribeiro; Andrea Riccio; Bonald C Figueiredo; Enzo Lalli
Journal:  Cancer Genet Cytogenet       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.